Figure 1. PTH (1-34)-induced luciferase expression in HEK293/PTH2/CRE-Luc cells. After stimulation by agonist PTH (1-34), the cells are determined with Fire-Lumi™ Luciferase Assay System (Cat. No. L00877C-100, Genscript) and the relative luminescence units (RLU) were recorded by plate reader (Pherastar, BMG). The RLU were plotted against the log of the cumulative doses of PTH (1-34) (Mean ± SEM, n = 3). The EC₅₀ of PTH (1-34) on cells was 0.68 nM.

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with PTH (1-34) in HEK293/PTH2/CRE-Luc cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in HEK293/PTH2/CRE-Luc cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC₅₀ of PTH (1-34) on cells was 23.07 nM.

293/PTH2/CRE-Luc Stable Cell Line

Recombinant HEK293 cells stably overexpress human parathyroid hormone 2 receptor (PTH2) on the surface and contain high levels of G protein Gαs and Gαq to couple with the receptor in downstream signaling pathways.

产品编号	M00270
规格	2 vials 大单询价
数量
价格	询价


联系我们

产品简介

Product Description	Recombinant HEK293 cells stably overexpress human parathyroid hormone 2 receptor (PTH2) on the surface and contain high levels of G protein Gαs and Gαq to couple with the receptor in downstream signaling pathways.
Culture Properties	Adherent
Stability	Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size	Two vials of frozen cells (>1×10⁶ per vial in 1 mL)
Storage	Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

培养条件

Culture Medium	DMEM, 10% FBS, 300 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies), 50 μg/ml Hygromycin B (Cat. No. 10687010, Invitrogen), 100 μg/ml Zeocin (Cat. No. R250-01, Life Technologies).
Complete Growth Medium	DMEM, 10% FBS
Freeze Medium-DATA	50% DMEM (Cat. No. 10566, Life Technologies), 45% FBS (Cat. No. 10099-141, Gibco), 5% DMSO (Cat. No. D2650, Sigma)

图例

Figure 1. PTH (1-34)-induced luciferase expression in HEK293/PTH2/CRE-Luc cells. After stimulation by agonist PTH (1-34), the cells are determined with Fire-Lumi™ Luciferase Assay System (Cat. No. L00877C-100, Genscript) and the relative luminescence units (RLU) were recorded by plate reader (Pherastar, BMG). The RLU were plotted against the log of the cumulative doses of PTH (1-34) (Mean ± SEM, n = 3). The EC₅₀ of PTH (1-34) on cells was 0.68 nM.

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with PTH (1-34) in HEK293/PTH2/CRE-Luc cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in HEK293/PTH2/CRE-Luc cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC₅₀ of PTH (1-34) on cells was 23.07 nM.

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

293/PTH2/CRE-Luc Stable Cell Line

资源中心

技术支持

关于我们